scholarly journals Hypoglycemia Prevention in Closed-Loop Artificial Pancreas for Patients with Type 1 Diabetes

10.5772/22647 ◽  
2011 ◽  
Author(s):  
Amjad Abu-Rmileh ◽  
Winston Garcia-Gabi
Keyword(s):  
Type 1 Diabetes ◽  
Closed Loop ◽  
Artificial Pancreas

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

2021 ◽  
Author(s):  
Coralie Amadou ◽  
Sylvia Franc ◽  
Pierre-Yves Benhamou ◽  
Sandrine Lablanche ◽  
Erik Huneker ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Adverse Events ◽  
Closed Loop ◽  
Artificial Pancreas ◽  
Real Life ◽  
Serious Adverse Events ◽  
Life Conditions ◽  
Time In Range

<b>OBJECTIVE </b> <p>To analyze safety and efficacy of the DBLG1 hybrid closed-loop artificial pancreas system in patients with Type 1 Diabetes in real life conditions. </p> <p> </p> <p><b>METHODS</b></p> <p>Following a one-week run-in period with usual pump, 25 patients were provided with the commercial DBLG1 system. We present the results of Time-in-Range and HbA1c over a 6-month period.</p> <p><b> </b></p> <p><b>RESULTS</b></p> <p>The mean (SD;range) age of patients was 43 years (13.8; 25-72). At baseline, mean HbA1c and TIR 70-180mg/dL were respectively 7.9% (0.93; 5.6- 8.5) [63mmol/mol (10; 38-69)] and 53% (16.4;21-85). One patient stopped using the system after 2 months. At 6-month, mean HbA1c decreased to 7.1% [54mmol/mol] (p<0.001) and TIR 70-180mg/dL increased to 69.7% (p<0.0001). TIR<70mg/dL decreased from 2.4 to 1.3% (p=0.03). TIR<54mg/dL decreased from 0.32 to 0.24% (p=0.42). No serious adverse event was reported during the study. </p> <p> </p> <p><b>CONCLUSION</b></p> <p>The DBLG1 System confirms its ability to significantly improve glycemic control in real life conditions, without serious adverse events. </p>

scholarly journals Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas

Diabetes Care ◽  
2008 ◽  
Vol 31 (5) ◽  
pp. 934-939 ◽  
Author(s):  
S. A. Weinzimer ◽  
G. M. Steil ◽  
K. L. Swan ◽  
J. Dziura ◽  
N. Kurtz ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Closed Loop ◽  
Pediatric Patients ◽  
Hybrid Control ◽  
Artificial Pancreas ◽  
Insulin Delivery

Artificial Pancreas With Carbohydrate Suggestion Performance for Unannounced and Announced Exercise in Type 1 Diabetes

2020 ◽  
Vol 106 (1) ◽  
pp. 55-63
Author(s):  
Clara Viñals ◽  
Aleix Beneyto ◽  
Juan-Fernando Martín-SanJosé ◽  
Clara Furió-Novejarque ◽  
Arthur Bertachi ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Closed Loop ◽  
Insulin Pump ◽  
Artificial Pancreas ◽  
Cycle Ergometer ◽  
Open Loop ◽  
Target Range ◽  
Exercise Session ◽  
And Performance

Abstract Objective To evaluate the safety and performance of a new multivariable closed-loop (MCL) glucose controller with automatic carbohydrate recommendation during and after unannounced and announced exercise in adults with type 1 diabetes (T1D). Research Design and Methods A randomized, 3-arm, crossover clinical trial was conducted. Participants completed a heavy aerobic exercise session including three 15-minute sets on a cycle ergometer with 5 minutes rest in between. In a randomly determined order, we compared MCL control with unannounced (CLNA) and announced (CLA) exercise to open-loop therapy (OL). Adults with T1D, insulin pump users, and those with hemoglobin (Hb)A1c between 6.0% and 8.5% were eligible. We investigated glucose control during and 3 hours after exercise. Results Ten participants (aged 40.8 ± 7.0 years; HbA1c of 7.3 ± 0.8%) participated. The use of the MCL in both closed-loop arms decreased the time spent &lt;70 mg/dL of sensor glucose (0.0%, [0.0-16.8] and 0.0%, [0.0-19.2] vs 16.2%, [0.0-26.0], (%, [percentile 10-90]) CLNA and CLA vs OL respectively; P = 0.047, P = 0.063) and the number of hypoglycemic events when compared with OL (CLNA 4 and CLA 3 vs OL 8; P = 0.218, P = 0.250). The use of the MCL system increased the proportion of time within 70 to 180 mg/dL (87.8%, [51.1-100] and 91.9%, [58.7-100] vs 81.1%, [65.4-87.0], (%, [percentile 10-90]) CLNA and CLA vs OL respectively; P = 0.227, P = 0.039). This was achieved with the administration of similar doses of insulin and a reduced amount of carbohydrates. Conclusions The MCL with automatic carbohydrate recommendation performed well and was safe during and after both unannounced and announced exercise, maintaining glucose mostly within the target range and reducing the risk of hypoglycemia despite a reduced amount of carbohydrate intake. Register Clinicaltrials.gov: NCT03577158

The Efficacy of Basal Rate and Carbohydrate Ratio Learning Algorithm for Closed-Loop Insulin Delivery (Artificial Pancreas) in Youth with Type 1 Diabetes in a Diabetes Camp

2020 ◽  
Vol 22 (3) ◽  
pp. 185-194 ◽  
Author(s):  
Emilie Palisaitis ◽  
Anas El Fathi ◽  
Julia E. Von Oettingen ◽  
Preetha Krishnamoorthy ◽  
Robert Kearney ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Closed Loop ◽  
Learning Algorithm ◽  
Artificial Pancreas ◽  
Insulin Delivery ◽  
Basal Rate ◽  
Diabetes Camp

scholarly journals The Bio-inspired Artificial Pancreas for Type 1 Diabetes Control in the Home: System Architecture and Preliminary Results

2019 ◽  
Vol 13 (6) ◽  
pp. 1017-1025 ◽  
Author(s):  
Pau Herrero ◽  
Mohamed El-Sharkawy ◽  
John Daniels ◽  
Narvada Jugnee ◽  
Chukwuma N. Uduku ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Type 1 Diabetes ◽  
Home Environment ◽  
Closed Loop ◽  
Artificial Pancreas ◽  
Target Range ◽  
Cell Physiology ◽  
Handheld Device ◽  
Preliminary Results

Background: Artificial pancreas (AP) technology has been proven to improve glucose and patient-centered outcomes for people with type 1 diabetes (T1D). Several approaches to implement the AP have been described, clinically evaluated, and in one case, commercialized. However, none of these approaches has shown a clear superiority with respect to others. In addition, several challenges still need to be solved before achieving a fully automated AP that fulfills the users’ expectations. We have introduced the Bio-inspired Artificial Pancreas (BiAP), a hybrid adaptive closed-loop control system based on beta-cell physiology and implemented directly in hardware to provide an embedded low-power solution in a dedicated handheld device. In coordination with the closed-loop controller, the BiAP system incorporates a novel adaptive bolus calculator which aims at improving postprandial glycemic control. This paper focuses on the latest developments of the BiAP system for its utilization in the home environment. Methods: The hardware and software architectures of the BiAP system designed to be used in the home environment are described. Then, the clinical trial design proposed to evaluate the BiAP system in an ambulatory setting is introduced. Finally, preliminary results corresponding to two participants enrolled in the trial are presented. Results: Apart from minor technical issues, mainly due to wireless communications between devices, the BiAP system performed well (~88% of the time in closed-loop) during the clinical trials conducted so far. Preliminary results show that the BiAP system might achieve comparable glycemic outcomes to the existing AP systems (~73% time in target range 70-180 mg/dL). Conclusion: The BiAP system is a viable platform to conduct ambulatory clinical trials and a potential solution for people with T1D to control their glucose control in a home environment.

scholarly journals A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes

2010 ◽  
Vol 2 (27) ◽  
pp. 27ra27-27ra27 ◽  
Author(s):  
F. H. El-Khatib ◽  
S. J. Russell ◽  
D. M. Nathan ◽  
R. G. Sutherlin ◽  
E. R. Damiano
Keyword(s):  
Type 1 Diabetes ◽  
Closed Loop ◽  
Artificial Pancreas
Sign in / Sign up

Export Citation Format

Share Document